Literature DB >> 27465670

The phenotype of newly diagnosed Graves' disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study.

L Bartalena1, E Masiello2, F Magri3, G Veronesi2,4, E Bianconi2, F Zerbini3, M Gaiti3, E Spreafico2, D Gallo2, P Premoli2, E Piantanida2, M L Tanda2, M Ferrario2,4, P Vitti5, L Chiovato3.   

Abstract

OBJECTIVE: The Merseburg triad (hyperthyroidism, goiter, and orbitopathy) characterizes classical description of Graves' disease (GD). Aim of this observational, longitudinal study was to evaluate the current clinical features of newly diagnosed GD in Italy.
MATERIALS AND METHODS: In two Northern Italy centers (Varese and Pavia), 283 consecutive patients (211 women, 72 men; mean age 47.4 years) with newly diagnosed GD were recruited in the years 2010-2014. Diagnosis was based on established criteria, and thyroid volume was assessed by ultrasonography. A clinical severity score (CSS) to assess the overall disease severity was developed by grading each component of the Merseburg triad.
RESULTS: At diagnosis, 45 % of patients had no goiter, and 30 % had a small goiter. The proportion of goitrous patients was much lower than in two Italian studies performed 20-30 years ago. Hyperthyroidism was subclinical in 16 % and mild in 29 % of patients, and Graves' orbitopathy was present in 20 %, usually mild, and active in only 2.5 % of patients. Using the CSS, less than half (44 %) of the patients had severe GD, while 22 % had mild and 34 % moderate disease. CSS was associated with a significantly higher risk of poorly controlled hyperthyroidism at 6 months.
CONCLUSIONS: In Italy, a relevant proportion of Graves' patients at diagnosis have mild to moderate GD; about half of them have no goiter, slightly less than one-fifth have subclinical hyperthyroidism, and only 20 % have GO. Thus, the clinical phenotype of GD is milder than in the past, possibly due to both earlier diagnosis and treatment, and improved iodine nutrition.

Entities:  

Keywords:  Antithyroid drugs; Goiter; Graves’ disease; Graves’ orbitopathy; Hyperthyroidism; Thyrotropin receptor antibody

Mesh:

Substances:

Year:  2016        PMID: 27465670     DOI: 10.1007/s40618-016-0516-7

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  24 in total

1.  Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment.

Authors:  P Vitti; T Rago; L Chiovato; S Pallini; F Santini; E Fiore; R Rocchi; E Martino; A Pinchera
Journal:  Thyroid       Date:  1997-06       Impact factor: 6.568

2.  Predicting the Risk of Recurrence Before the Start of Antithyroid Drug Therapy in Patients With Graves' Hyperthyroidism.

Authors:  Xander G Vos; Erik Endert; A H Zwinderman; Jan G P Tijssen; Wilmar M Wiersinga
Journal:  J Clin Endocrinol Metab       Date:  2016-02-10       Impact factor: 5.958

3.  Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study.

Authors:  Carlo Cappelli; Elena Gandossi; Maurizio Castellano; Claudio Pizzocaro; Barbara Agosti; Andrea Delbarba; Ilenia Pirola; Elvira De Martino; Enrico Agabiti Rosei
Journal:  Endocr J       Date:  2007-08-03       Impact factor: 2.349

4.  Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO.

Authors:  Luigi Bartalena; Lelio Baldeschi; Alison Dickinson; Anja Eckstein; Pat Kendall-Taylor; Claudio Marcocci; Maarten Mourits; Petros Perros; Kostas Boboridis; Antonella Boschi; Nicola Currò; Chantal Daumerie; George J Kahaly; Gerasimos E Krassas; Carol M Lane; John H Lazarus; Michele Marinò; Marco Nardi; Christopher Neoh; Jacques Orgiazzi; Simon Pearce; Aldo Pinchera; Susanne Pitz; Mario Salvi; Paolo Sivelli; Matthias Stahl; Georg von Arx; Wilmar M Wiersinga
Journal:  Eur J Endocrinol       Date:  2008-03       Impact factor: 6.664

5.  Detection of thyroid growth immunoglobulins (TGI) by [3H]-thymidine incorporation in cultured rat thyroid follicles.

Authors:  L Chiovato; L J Hammond; T Hanafusa; R Pujol-Borrell; D Doniach; G F Bottazzo
Journal:  Clin Endocrinol (Oxf)       Date:  1983-11       Impact factor: 3.478

6.  Medical therapy of Graves' disease: effect on remission rates of methimazole alone and in combination with triiodothyronine.

Authors:  W Raber; E Kmen; W Waldhäusl; H Vierhapper
Journal:  Eur J Endocrinol       Date:  2000-02       Impact factor: 6.664

7.  Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.

Authors:  D Glinoer; P de Nayer; M Bex
Journal:  Eur J Endocrinol       Date:  2001-05       Impact factor: 6.664

8.  Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment?

Authors:  L Tallstedt; G Lundell; H Blomgren; J Bring
Journal:  Eur J Endocrinol       Date:  1994-05       Impact factor: 6.664

9.  Antibodies that promote thyroid growth. A distinct population of thyroid-stimulating autoantibodies.

Authors:  W A Valente; P Vitti; C M Rotella; M M Vaughan; S M Aloj; E F Grollman; F S Ambesi-Impiombato; L D Kohn
Journal:  N Engl J Med       Date:  1983-10-27       Impact factor: 91.245

Review 10.  Extrathyroidal manifestations of Graves' disease: a 2014 update.

Authors:  Luigi Bartalena; Vahab Fatourechi
Journal:  J Endocrinol Invest       Date:  2014-06-10       Impact factor: 4.256

View more
  19 in total

1.  A milder phenotype of Graves' disease in recent years in Italy.

Authors:  A Ponzetto; N Figura
Journal:  J Endocrinol Invest       Date:  2016-11-15       Impact factor: 4.256

Review 2.  Preoperative management in patients with Graves' disease.

Authors:  Eliana Piantanida
Journal:  Gland Surg       Date:  2017-10

3.  Antithyroid drug treatment for Graves' disease: baseline predictive models of relapse after treatment for a patient-tailored management.

Authors:  E Masiello; G Veronesi; D Gallo; P Premoli; E Bianconi; S Rosetti; C Cusini; J Sabatino; S Ippolito; E Piantanida; M L Tanda; L Chiovato; W M Wiersinga; L Bartalena
Journal:  J Endocrinol Invest       Date:  2018-06-26       Impact factor: 4.256

4.  Graves' orbitopathy, idiopathic orbital inflammatory pseudotumor and Epstein-Barr virus infection: a serological and molecular study.

Authors:  M Leo; F Maggi; G R Dottore; G Casini; P Mazzetti; M Pistello; S Sellari-Franceschini; M Nardi; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2016-12-16       Impact factor: 4.256

Review 5.  Polyglandular autoimmune syndromes.

Authors:  G J Kahaly; L Frommer
Journal:  J Endocrinol Invest       Date:  2017-08-17       Impact factor: 4.256

6.  The clinical phenotype of Graves' disease occurring as an isolated condition or in association with other autoimmune diseases.

Authors:  M Rotondi; C Virili; S Pinto; F Coperchini; L Croce; N Brusca; M Centanni; L Chiovato
Journal:  J Endocrinol Invest       Date:  2019-08-12       Impact factor: 4.256

Review 7.  Global epidemiology of hyperthyroidism and hypothyroidism.

Authors:  Peter N Taylor; Diana Albrecht; Anna Scholz; Gala Gutierrez-Buey; John H Lazarus; Colin M Dayan; Onyebuchi E Okosieme
Journal:  Nat Rev Endocrinol       Date:  2018-03-23       Impact factor: 43.330

8.  Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?

Authors:  L Bartalena; G Veronesi; G E Krassas; W M Wiersinga; C Marcocci; M Marinò; M Salvi; C Daumerie; C Bournaud; M Stahl; L Sassi; C Azzolini; K G Boboridis; M P Mourits; M R Soeters; L Baldeschi; M Nardi; N Currò; A Boschi; M Bernard; G von Arx; P Perros; G J Kahaly
Journal:  J Endocrinol Invest       Date:  2017-02-07       Impact factor: 4.256

9.  Does Graves' Orbitopathy Ever Disappear? Answers to an Old Question.

Authors:  Elena Sabini; Marenza Leo; Barbara Mazzi; Roberto Rocchi; Francesco Latrofa; Marco Nardi; Paolo Vitti; Claudio Marcocci; Michele Marinò
Journal:  Eur Thyroid J       Date:  2017-06-26

10.  Long-term remission following antithyroid drug withdrawal in patients with Graves' hyperthyroidism: parameters with prognostic value.

Authors:  Ricardo V García-Mayor; Paula Álvarez-Vázquez; Enrique Fluiters; Diana Valverde; Amalia Andrade
Journal:  Endocrine       Date:  2018-10-17       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.